CTC Story


> CTC Story > Application

Companion diagnosis is an in vitro test that provides information essential for the safe and effective use of a corresponding drug.
CytoGen's CTC-liquid biopsy platform can be used for companion diagnostics, which widens available options for cancer treatment. Our platform helps patients unable to get tissue biopsy to elucidate the characteristics of cancer through CTC analysis. This analysis can be done with a minimally invasive method and serial collection of blood. The CTC profiling achieved through our system ultimately contributes to increasing the effectiveness of cancer treatment by selecting optimal drugs for different individuals, and by monitoring cancer prognosis.

Global Liquid Biopsy Network

The collective CTC data via global networks are processed and accumulated as big data.

CytoGen's Liquid Biopsy Platform

CTC-based liquid biopsy platform is applicable to any stages of anti-cancer drug development procedures.

Clinical Applications using CytoGen’s platform

Characterization of CTCs with specific cancer type biomarkers is available for clinical application
  • Lung Cancer

  • Pancreas Cancer

  • Bile duct Cancer

  • Prostate Cancer

  • Gastric Cancer

  • Head & Neck Cancer

  • Breast Cancer

  • Colon Cancer

  • Brain Cancer

  • Esophageal Cancer

  • Liver Cancer

  • Sarcoma

  • Ovarian Cancer

CTC-based biomarkers available at CytoGen

EpCAM/CK/Vimentin+, CD45-, AXL+, HER2+, HER3, Trop2+, PD-L1+, tEGFR+, pEGFR+(Y845), pEGFR+(Y1045), mut.EGFR+(L858R), CD133+, AR-V7+, AR+, PSMA+, Nortch1, pERK+, pEGFR+, pEGFR+, mut.EGFR, EGRFvlll+, GFAP+, PD-L1, PanCK+, FOLR1, HE-4+